Top Stories

The Growth of Stem Cell Applications are Contributing to the Cell Therapy Processing Market

Posted: 7th August 2018 10:03

According to a report published by BCC Research, the cell therapy processing market is expected to reach USD 5 Billionby 2022 while growing at a compound annual growth rate of 30.9% during forecast year. Based on offering type, the market can be segmented into a variety of products (cell lines, instruments, among others), services (product design, process design, among others) and software (enabling software). The products sector is expected to hold the largest share in the market and reach USD 4.01 Billion by 2022, while the software sector is expected to grow at the fastest rate during the forecast years as software makes the workflow of cell therapy processing easier and more efficient. Avalon GloboCare Corp. (OTC: AVCO), Syndax Pharmaceuticals Inc.

Robert G. Hunter, BCC Research Senior Editor, Healthcare, said, "The factors that drive the growth of the cell therapy processing market include success of hematopoietic stem cell transplantation for treatment of a variety of blood cancers and hematologic conditions, rise in the demand for chimeric antigen receptor (CAR) T cell therapy, and an increase in the development of stem cell therapy applications and approaches. Additionally, the rise in the development of allogeneic cell therapy offer better opportunities for profitability supports market growth."

Avalon GloboCare Corp. (OTCQB: AVCO) announced earlier in June that it has, "appointed Steven Sanders, Esq. to the Board of Directors.

Mr. Sanders brings over four decades of experience within the specialized areas of corporate, securities and international law. He has experience representing life science companies including both public and private companies. He has also represented both underwriters and issuers on a variety of public and private financings. He has held senior positions at leading U.S. and international law firms, and founded the Ortoli Rosenstadt LLP law firm, headquartered in New York City, which has represented both domestic and international clients across many industries including life sciences, in areas such as mergers, acquisitions and a variety of other transactions. Steven is a member of the American Bar Association and the New York State Bar Association and the Bar of the City of New York, where he previously served on the European Affairs Committee. In addition, Mr. Sanders sits on the boards of other companies including Helijet International Inc. and Electrameccanica Vehicles, as well as non-profits such as the American Academy of Dramatic Arts, and the Bay Street Theater. He previously served on the board of the Roundabout Theatre Company, the largest non-profit theater in America and Town Hall. He also was the former Honorary Consul from the Republic of Moldova."

Dr. David Jin, President and CEO of Avalon GloboCare, stated, "We are pleased to welcome Steven Sanders to our Board of Directors. He brings an impressive corporate and international law background, as well as extensive capital markets and M&A experience. He also brings a wealth of knowledge in the life sciences industry. Steve will be an invaluable asset as we pursue strategic partnerships and acquisitions within the cell-therapy industry."

Steven Sanders commented, "I am delighted to join Avalon's Board of Directors. The field of cell therapy is undergoing rapid transformation, as evidenced by recent advancements in immuno-oncology and regenerative medicine. Avalon's exosome technologies and cell-based therapies, as well as its network of leading research institutions in the U.S. and China, place it at the forefront of this emerging market. I look forward to helping Avalon advance its mission of bringing cutting-edge therapies to market and saving lives."

Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) is a biopharmaceutical company developing an innovative pipeline of cancer therapies at various stages of clinical and pre-clinical development. On May 30th, 2018, the Company and Nektar Therapeutics announced a non-exclusive, clinical collaboration to evaluate the safety and efficacy of Nektar's NKTR-214, a CD122-biased agonist, in combination with entinostat, Syndax's oral, small molecule Class 1 specific HDAC inhibitor, in patients with metastatic melanoma who have previously progressed on treatment with an anti-PD-1 (programmed death receptor-1) agent. In preclinical testing, the results of which were recently presented at the 2018 American Association of Cancer Research Annual Meeting, the combination of entinostat and NKTR-214 significantly inhibited tumor growth in tumor models of kidney and colon cancer. The anti-tumor activity of the combination was accompanied by a dramatic increase in the activation and cytotoxic activity of CD8+ T cells in the tumor, along with modulation of immune suppressor cells found in the tumor microenvironment.

Sorrento Therapeutics Inc. (NASDAQ: SRNE) is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies, clinical stage immuno-cellular therapies ('CAR-T'), intracellular targeting antibodies ('iTAbs'), antibody-drug conjugates ('ADC'), and clinical stage oncolytic virus ('Sephrevir®'). Recently, the Company and Celularity Inc. announced that they have started screening patients for its leading CD38 chimeric antigen receptor (CAR) T cell therapy drug development program, following FDA review allowing clinical trial initiation. The Companies' CD38 CAR-T program is their most advanced program targeting this difficult-to-treat condition. This trial is currently the only active US-based clinical trial targeting CD38 using a CAR-T cell therapy.

Athersys Inc. (NASDAQ: ATHX) is an international biotechnology company engaged in the development of therapeutic products designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived 'off-the-shelf' stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Recently, the Company announced that the first patient has been enrolled its Phase 3 study entitled, MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 ('MASTERS-2') to evaluate MultiStem® cell therapy treatment of patients who have suffered an ischemic stroke. The MASTERS-2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial designed to enroll 300 patients in North America and Europe who have suffered moderate to moderate-severe ischemic stroke. The enrolled subjects will receive either a single intravenous dose of MultiStem cell therapy or placebo, administered within 18 to 36 hours of the occurrence of the stroke, in addition to the standard of care.

Ziopharm Oncology Inc. (NASDAQ: ZIOP) is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. Recently, the Company announced the U.S. Food and Drug Administration (FDA) placed on clinical hold a Phase 1 trial to evaluate CD19-specific CAR-T therapies manufactured under point-of-care and requested additional information in support of the investigational new drug (IND) application for the trial. Ziopharm, Precigen Inc., a wholly-owned subsidiary of Intrexon Corporation and The University of Texas MD Anderson Cancer Center, the IND sponsor, are seeking to conduct a clinical trial to evaluate CAR+ T cells manufactured with Sleeping Beauty technology as an investigational treatment for patients with relapsed or refractory, CD19+ leukemias and lymphomas. CAR+ T cells very-rapidly manufactured with the Sleeping Beauty platform for this third-generation trial are designed to co-express CD19-specific chimeric antigen receptor, or CAR, membrane-bound interleukin 15 and a safety switch. The FDA has requested additional information relative to Chemistry, Manufacturing and Controls. Ziopharm and its partners will address the FDA's requests, and the initiation of this trial may be delayed.

Subscribe Now! Watch us report LIVE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

Related articles